Provided by Tiger Fintech (Singapore) Pte. Ltd.

Contineum Therapeutics, INC.

6.67
-0.4700-6.58%
Post-market: 6.670.00000.00%16:05 EDT
Volume:61.60K
Turnover:419.22K
Market Cap:171.94M
PE:-3.11
High:7.28
Open:7.18
Low:6.42
Close:7.14
Loading ...

Contineum Says US FDA Clears IND Application for PIPE-791 to Treat Chronic Pain Linked to Osteoarthritis, Low Back Pain

MT Newswires Live
·
18 Nov 2024

BRIEF-Contineum Therapeutics Expands Clinical Development Of PIPE-791

Reuters
·
18 Nov 2024

Contineum announces FDA authorization for PIPE-791

TIPRANKS
·
18 Nov 2024

Contineum Therapeutics Inc - Topline Data From Pipe-791 Study Expected in Early 2026

THOMSON REUTERS
·
18 Nov 2024

Contineum Therapeutics Expands Clinical Development of Pipe-791 With FDA Authorization of Its Investigational New Drug (Ind) Application for Chronic Pain

THOMSON REUTERS
·
18 Nov 2024

Contineum Therapeutics Inc: Phase 1B Study for Potential Treatment of Osteoarthritis and Low Back Pain Expected to Commence in Q1 of 2025

THOMSON REUTERS
·
18 Nov 2024

Contineum Therapeutics Inc - Expects $213.9 Mln Cash to Fund Operations Through 2027

THOMSON REUTERS
·
18 Nov 2024

Contineum Therapeutics Expands Clinical Development of PIPE-791 With FDA Authorization of Its Investigational New Drug (IND) Application for Chronic Pain

Business Wire
·
18 Nov 2024

Contineum Therapeutics to Attend Upcoming Investor Conferences

Business Wire
·
14 Nov 2024

Contineum Therapeutics, Inc. Class A (CTNM) Receives a Buy from Morgan Stanley

TIPRANKS
·
07 Nov 2024

RBC Adjusts Contineum Therapeutics' Price Target to $31 From $32, Keeps Outperform Speculative Risk Rating

MT Newswires Live
·
07 Nov 2024

U.S. RESEARCH ROUNDUP-BXP, Hubspot, Qualcomm

Reuters
·
07 Nov 2024

Contineum Therapeutics Inc : RBC Cuts Target Price to $31 From $32

THOMSON REUTERS
·
07 Nov 2024

Contineum Therapeutics Inc : Qtrly Shr Loss $0.40

THOMSON REUTERS
·
07 Nov 2024

Stifel Nicolaus Reaffirms Their Buy Rating on Contineum Therapeutics, Inc. Class A (CTNM)

TIPRANKS
·
31 Oct 2024

Baird Initiates Contineum Therapeutics at Outperform With $32 Price Target

MT Newswires Live
·
22 Oct 2024